Strategic Focus: Recent chatter on X about Illumina, Inc. (ILMN) has zeroed in on the company’s strategic moves after a prominent healthcare conference. Posts highlight optimism around the CEO’s plans to tackle challenges like the Grail spin-off. There’s also buzz about new tech in the spatial market gaining traction.
Financial Updates: Discussions on X also touch on Illumina’s financial maneuvers, including a recent $500 million notes offering for expansion. Some users note stronger-than-expected quarterly results as a positive sign. However, concerns linger about policy headwinds impacting growth.
Market Sentiment: The tone on X shows a mix of hope and caution regarding Illumina’s future. A few posts mention analyst upgrades boosting confidence in the stock’s prospects. The narrative seems to be shifting as the company addresses past hurdles.
Note: This discussion summary was generated from an AI condensation of post data.
Illumina, Inc. Insider Trading Activity
Illumina, Inc. insiders have traded $ILMN stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ILMN stock by insiders over the last 6 months:
- SCOTT GOTTLIEB purchased 500 shares for an estimated $61,065
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Illumina, Inc. Congressional Stock Trading
Members of Congress have traded $ILMN stock 4 times in the past 6 months. Of those trades, 2 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $ILMN stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN has traded it 4 times. They made 2 purchases worth up to $30,000 on 10/30, 06/09 and 2 sales worth up to $30,000 on 10/31, 10/30.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Illumina, Inc. Hedge Fund Activity
We have seen 380 institutional investors add shares of Illumina, Inc. stock to their portfolio, and 415 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL WORLD INVESTORS added 3,331,542 shares (+20.0%) to their portfolio in Q3 2025, for an estimated $316,396,543
- NORGES BANK removed 1,471,904 shares (-86.0%) from their portfolio in Q2 2025, for an estimated $140,434,360
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 1,383,109 shares (+77.0%) to their portfolio in Q3 2025, for an estimated $131,353,861
- POINTSTATE CAPITAL LP removed 1,150,354 shares (-39.0%) from their portfolio in Q3 2025, for an estimated $109,249,119
- SOMA EQUITY PARTNERS LP removed 933,750 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $89,089,087
- THRIVENT FINANCIAL FOR LUTHERANS added 674,033 shares (+4082.6%) to their portfolio in Q3 2025, for an estimated $64,012,914
- BLACKROCK, INC. removed 671,290 shares (-3.5%) from their portfolio in Q3 2025, for an estimated $63,752,411
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Illumina, Inc. Government Contracts
We have seen $32,847,676 of award payments to $ILMN over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- ILLUMINA REAGENT CHEMISTRY KITS: $1,368,526
- ILLUMINA REAGENTS AND CONSUMABLES: $999,049
- ILLUMINA DRAGEN GENOMIC ANALYSIS SYSTEM: $663,214
- PURCHASE NEXTSEQ 2000 SEQUENCING SYSTEM & BRONZE SUPPORT PLAN FOR THE NOAA FISHERIES, SOUTHWEST FISHERIES S...: $658,767
- ILLUMINA REAGENT CHEMISTRY KITS: $647,412
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
Illumina, Inc. Analyst Ratings
Wall Street analysts have issued reports on $ILMN in the last several months. We have seen 2 firms issue buy ratings on the stock, and 2 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Underweight" rating on 10/31/2025
- Evercore ISI Group issued a "Outperform" rating on 10/07/2025
- RBC Capital issued a "Outperform" rating on 08/01/2025
- Citigroup issued a "Sell" rating on 07/09/2025
To track analyst ratings and price targets for Illumina, Inc., check out Quiver Quantitative's $ILMN forecast page.
Illumina, Inc. Price Targets
Multiple analysts have issued price targets for $ILMN recently. We have seen 11 analysts offer price targets for $ILMN in the last 6 months, with a median target of $112.0.
Here are some recent targets:
- Luke Sergott from Barclays set a target price of $100.0 on 10/31/2025
- Vijay Kumar from Evercore ISI Group set a target price of $142.0 on 10/31/2025
- Dan Brennan from TD Cowen set a target price of $115.0 on 10/31/2025
- Kyle Mikson from Canaccord Genuity set a target price of $112.0 on 10/31/2025
- Casey Woodring from JP Morgan set a target price of $105.0 on 10/31/2025
- John Sourbeer from UBS set a target price of $120.0 on 10/31/2025
- Tejas Savant from Morgan Stanley set a target price of $105.0 on 08/04/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
